Correctly distinguishing between related neurodegenerative diseases remains challenging for clinicians, because reliable markers do not yet exist for many disorders. In the July 22 Neurology, ...
Imatinib (STI571) plus hydroxyurea: Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts) No significant financial relationships to disclose. This is an ASCO ...
(Barcelona, Spain, Wednesday 8 September 2025) The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual ...
Expert Rev Anticancer Ther. 2009;9(1):75-96. Based on the available data, FDG-PET alone appears to be of limited use in differentiating tumors of low malignant potential from benign tumors and ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results